John Shamsey, Bristol-Myers Squibb
S
John Shamsey
Senior director, managed markets strategy, Bristol-Myers Squibb
ACTIVE IN: Academy of Managed Care Pharmacy
USES: Longitudinal data to develop national account strategies
Medicare Part D had a significant impact on the industry, but John Shamsey, age 39, was ready for it. He had focused on managed markets early in his career, becoming versed in the intricacies of payers while his marketing colleagues considered the it an afterthought. As a result, Shamsey has become an unofficial spokesperson for Part D, explaining to colleagues in the company and the rest of the industry just how the whole thing works.
John Shamsey
"It gave me a chance to offer insight to others about what Medicare means to our current product portfolio, as well as for future products' value proposition development," says Shamsey. "The impact that managed markets and payers are having on our business will be really important for leaders to understand and to incorporate the perspective into the business."
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Pfizer, GSK Gain ACIP Recommendations for RSV and Meningococcal Vaccines
April 18th 2025The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in their 50s and voted in favor of GSK’s meningococcal vaccine, Penmenvy, for streamlined adolescent protection.
